

CoMMa: Contribution-Aware Medical Multi-Agents for Decentralized Oncology Decision Support

Yichen Wu^{1*}, Kailong Fan^{1*}, Sangjoon Park^{2*}, Yuhan Liu³, Zhiyi Shi¹,
Sekeun Kim¹, Dania Daye⁴, Hana Farzaneh¹, Wei Liu⁵, Xiang Li^{1†},
Raul Uppot¹, Yujin Oh^{1,3†}, Quanzheng Li^{1†}

¹Harvard Medical School/MGH, ²Yonsei University, ³MBZUAI, ⁴UW-Madison, ⁵Mayo Clinic
{yiwu6, kfan5}@mgh.harvard.edu,

Abstract

Recent multi-agent frameworks have shown promise for oncology decision support, yet most assume centralized data access and rely on prompt-based assignment, limiting their applicability in privacy-sensitive clinical settings. We propose Contribution-Aware Medical Multi-Agents (CoMMa), a decentralized LLM-agent framework where specialists operate on partitioned clinical data streams. Unlike prior approaches that share inputs across agents, CoMMa enforces data decentralization to include stronger role specialization and further enhances this via agent-specific finetuning. To enable reliable and interpretable coordination, we introduce a contribution-aware aggregation mechanism that replaces stochastic, narrative-based reasoning with deterministic embedding projections to approximate each agent’s marginal utility. This yields explicit credit assignment over agents, providing a stable and interpretable decision pathway aligned with clinical requirements. We evaluate CoMMa on multiple oncology benchmarks, including real-world multidisciplinary tumor board datasets from large academic hospitals in North America and East Asia, as well as public datasets, demonstrating strong performance and generalization across heterogeneous clinical settings.

1 Introduction

Effective clinical decision support in oncology, such as treatment recommendation, prognosis estimation, and recurrence prediction, requires the seamless integration of longitudinal, heterogeneous data. In practice, this process is carried out through multidisciplinary tumor boards [27, 22], where clinicians jointly discuss patient histories, medical imaging, pathology findings, and evolving laboratory markers. Recently, large language model (LLM)-based multi-agents systems have emerged as a promising paradigm for this setting, distributing complex reasoning across specialized agents to better reflect multidisciplinary workflows [4, 17, 10, 13, 8].

Despite their promise, most existing medical multi-agent frameworks rely on role-based prompting, where agents are assigned clinician-like roles such as oncologists or radiologists [4, 17, 31]. As shown in Fig. 1(b), these agents typically share the same full patient information and communicate through natural language discussion. However, because all agents access the same full patient context, their specialization is mainly defined by prompts rather than distinct clinical evidence or domain-specific adaptation. As a result, agents with different clinical roles often rely on overlapping evidence, making it difficult to determine which information or which agent contributes most to the final decision, even though such interpretability is particularly important in clinical decision-making. Compared with the single-agent setting in Fig. 1(a), current multi-agent frameworks in Fig. 1(b) provide improved

*Equal Contribution

†Corresponding author: and Yujin Oh(yujinoh@yuhs.ac), Xiang Li and Quanzheng Li(xli60/quanzheng@mgh.harvard.edu)




Figure 1: Comparison of medical decision-making frameworks. (a) Single-agent and (b) role-based multi-agent systems rely on shared inputs and narrative reasoning. (c) CoMMA introduces decentralized data streams, agent-specific specialization, and contribution-aware aggregation for interpretable and stable clinical decision-making. (d) Summary table comparing key design elements across the three decision-making frameworks under a unified formulation.

collaboration, but still depend on shared patient context, limited structural specialization, and weak attribution of agent contributions in complex, real-world clinical decision workflows.

To address these limitations, we propose Contribution-Aware Medical Multi-Agents (CoMMA), a framework that moves beyond prompt-based role assignment toward data-decentralized and contribution-aware specialization. As illustrated in Fig. 1(c), CoMMA partitions the clinical context into distinct evidence streams and assigns each stream to a dedicated agent, enabling specialization through separate clinical evidence rather than persona simulation alone. Each agent further uses a domain-specific adaptation module to strengthen specialty-aware representations. Agents then exchange information through deterministic representation-level collaboration, producing updated agent states without relying on free-form natural language discussion.

To support interpretable clinical decision-making, the proposed CoMMA introduces a contribution-aware aggregation mechanism that explicitly models the relative contribution of each specialist agent to the final prediction. Inspired by cooperative game theory, CoMMA regularizes agent contributions using Shapley-based marginal utility estimation [24, 2], enabling more transparent and structured multi-agent reasoning. This design enables structurally specialized collaboration and explicit agent-level attribution without requiring full-context sharing across agents, as summarized in Fig. 1 (c)(d). We evaluate CoMMA across diverse oncology benchmarks, including real-world multidisciplinary tumor board datasets from large academic hospitals in North America and East Asia, together with public benchmarks. Experimental results demonstrate that CoMMA consistently improves predictive performance, decision stability, and attribution interpretability across multiple open-source LLM backbones and clinical decision-making tasks.

In summary, our core contributions are summarized as follows:

- We propose CoMMA, a decentralized medical multi-agent framework that enables structurally specialized reasoning without requiring full-context sharing across agents.
- We introduce a Shapley-regularized contribution-aware aggregation strategy, enabling explicit attribution for interpretable clinical decision-making.

- We validate CoMMa across multiple open-source LLM backbones and diverse real-world oncology benchmarks from large academic hospitals in North America and East Asia, demonstrating consistent improvements over existing single-agent and multi-agent baselines.

2 Related Works

Multi-Agents for Medical Applications. Recent studies have explored multi-agent LLM systems for collaborative clinical decision-making, where agents take specialized medical roles [5, 25, 33, 16, 30, 32, 1, 8]. MedAgents [26] frames problem-solving as a multi-physician debate with answer aggregation, while MDAgents [17] adaptively chooses single-versus multi-agent collaboration to balance accuracy and cost. Beyond free-form discussion, Multi-Agent Conversation [4] structures deliberation to mimic multidisciplinary meetings, and AI Hospital [9] evaluates longitudinal reasoning in a multi-agent clinical simulation. However, these systems are primarily role-based: collaboration is mediated through narrative exchanges and the final decision is fused implicitly, making evidence-level contribution hard to quantify. In contrast, our contribution-aware framework explicitly attributes how each evidence source and agent influences the final prediction, enabling more controlled fusion and more reliable clinical decision outputs.

Game Theory in Clinical Decision-Making. Game theory provides mathematical frameworks for modeling strategic interactions among rational agents and has been widely applied in general-domain decision-making, including economics, management, defense, and computer science [29, 7, 15, 21, 18]. Despite its strong theoretical foundations, its adoption in clinical settings remains limited [20, 19], particularly in oncology. Oncology decision-making relies on heterogeneous and interdependent evidence sources, where quantifying the contribution of each component is essential for interpretability and clinical reliability. Among cooperative game-theoretic approaches, the Shapley value [24, 2] provides a principled and axiomatized solution for fair allocation of a total payoff among participating agents. In a clinical AI setting, the payoff corresponds to the final clinical decision or predictive outcome, while each agent represents a distinct modality or specialized source of clinical information. The Shapley value of an agent is defined as its expected marginal contribution, averaged over all possible coalitions, satisfying desirable payoff. To the best of our knowledge, this work is the first to incorporate Shapley value-based contribution modeling as a regularization mechanism in a multi-agent oncological tumor board framework.

3 Method

To enable structurally specialized and interpretable clinical decision-making, we propose CoMMa, a contribution-aware multi-agent framework for clinical outcome prediction. Given heterogeneous patient information $\mathbf{x} = \{\mathbf{x}_1, \dots, \mathbf{x}_N\}$, each $\mathbf{x}_i$ denotes a distinct clinical evidence stream, such as imaging findings, laboratory measurements, staging information, or clinical history. Instead of concatenating all streams into a single input, CoMMa keeps them separated and assigns each stream to a specialist agent. The framework then learns how much each agent should contribute to each prediction for each patient. The design preserves the complementary structure of clinical evidence and provides explicit agent-level attribution for the final decision.

As illustrated in Fig. 2, patient evidence is first partitioned into decentralized clinical streams and processed by specialist agents. Each stream is encoded using a frozen open-source LLM encoder followed by a lightweight trainable specialty projection module, producing agent-specific representations. These representations are then refined through cross-agent collaborative reasoning, allowing specialist agents to exchange complementary information while maintaining their evidence-specific roles. Finally, CoMMa performs contribution-aware aggregation through a sample-specific fusion gate regularized by a Shapley contribution estimator, generating the final clinical prediction with explicit attribution of agent contributions.

3.1 Decentralized Specialist Encoding

CoMMa constructs each specialist agent with restricted access to one clinical evidence stream. The i -th agent observes only $\mathbf{x}_i$, rather than the full patient context, so its role is defined by its observation space instead of textual role prompting. Concretely, each stream is encoded by a frozen LLM backbone and an agent-specific trainable projection head:

$$\mathbf{e}_i = \text{LLM}_{\text{frozen}}(\mathbf{x}_i)[\text{<CLS>}], \quad \mathbf{h}_i = f_{\theta_i}(\mathbf{e}_i), \quad i = 1, \dots, N, \quad (1)$$




Figure 2: Architectural overview of CoMMA for decentralized multi-agent oncology decision support. Patient evidence is partitioned into distinct clinical streams and processed by specialist agents with separate observation spaces. Agent-specific representations are refined through cross-agent collaborative reasoning and aggregated by a sample-specific contribution gate regularized with Shapley-based attribution during model training.

where $\mathbf{e}_i \in \mathbb{R}^d$ is the deterministic representation of the i -th evidence stream, and $\mathbf{h}_i \in \mathbb{R}^C$ denotes the agent output over C prediction targets. The projection head f_{θ_i} is optimized only for its assigned stream, enabling agent-specific adaptation while keeping the LLM backbone fixed.

This decentralized design allows specialist agents to maintain distinct observation spaces and representation pathways throughout collaborative decision-making. In practice, frozen LLM embeddings are cached and reused, so training focuses on the lightweight agent-specific modules.

3.2 Cross-Agent Collaborative Reasoning

Although each specialist agent observes only one clinical evidence stream, effective clinical decision-making still requires integrating complementary information across agents. CoMMA therefore performs collaboration only after decentralized encoding, where agents exchange compact latent representations instead of accessing each other’s raw clinical evidence or the full patient context.

For each agent, we summarize the peer representations by averaging the outputs of all other agents, and the i -th agent then refines its representation through a gated residual update:

$$\bar{\mathbf{h}}_{-i} = \frac{1}{N-1} \sum_{j \neq i} \mathbf{h}_j, \quad \hat{\mathbf{h}}_i = \mathbf{h}_i + \rho \sigma(g_\psi([\mathbf{h}_i, \bar{\mathbf{h}}_{-i}])) \odot u_\psi([\mathbf{h}_i, \bar{\mathbf{h}}_{-i}]). \quad (2)$$

Here, g_ψ and u_ψ are lightweight trainable networks, $\sigma(\cdot)$ denotes the sigmoid function, $\odot$ denotes element-wise multiplication, and ρ controls the residual update scale. This interaction enables each agent to incorporate complementary peer signals while preserving its own evidence-specific representation throughout collaborative clinical decision-making. Unlike natural language debate, the collaboration is deterministic and operates directly on compact agent-level representations.

3.3 Contribution-Aware Aggregation and Learning

After cross-agent collaborative reasoning, CoMMA aggregates the refined specialist outputs through a sample-specific contribution gate. For each patient and prediction target, the gate assigns a normalized weight to each agent based on its refined representation:

$$W_{i,k} = \frac{\exp\left(G_\phi(\hat{\mathbf{h}}_i, \mathbf{H})_k / \tau\right)}{\sum_{j=1}^N \exp\left(G_\phi(\hat{\mathbf{h}}_j, \mathbf{H})_k / \tau\right)}, \quad \hat{y}_k = \sum_{i=1}^N W_{i,k} \hat{h}_{i,k}, \quad (3)$$

where $\mathbf{H} = \{\hat{\mathbf{h}}_1, \dots, \hat{\mathbf{h}}_N\}$, G_ϕ is a lightweight contribution gate, τ is a temperature parameter, and $\hat{y}_k$ is the prediction for target k . The matrix $\mathbf{W}$ provides a target-specific decomposition of the final prediction across specialist agents.

Learning meaningful contribution weights requires more than prediction supervision alone. CoMMA therefore optimizes three complementary objectives:

$$\mathcal{L}_{\text{total}} = \mathcal{L}_{\text{BCE}}(\hat{\mathbf{y}}, \mathbf{y}) + \lambda_{\text{pg}} \mathcal{L}_{\text{pg}} + \lambda_{\text{shap}} \mathcal{L}_{\text{shap}}. \quad (4)$$

Objective. $\mathcal{L}_{\text{BCE}}$ optimizes the final clinical prediction; $\mathcal{L}_{\text{pg}}$ encourages agents with higher marginal utility to receive larger contribution weights; $\mathcal{L}_{\text{shap}}$ regularizes the learned weights using Shapley-based coalition utility, enabling more stable and interpretable contribution attribution.

Utility-guided contribution learning. To align the contribution gate with each agent’s actual predictive utility, CoMMA first estimates how much each specialist agent contributes to the final prediction. We adopt a leave-one-out strategy that measures the prediction loss change after removing one agent from the aggregation process. Let $\bar{\mathbf{y}}$ denote the aggregated prediction using all refined agents, and let $\bar{\mathbf{y}}_{-i}$ denote the corresponding prediction after excluding agent i . The marginal utility of agent i for target k is defined as

$$r_{i,k} = \mathcal{L}_{\text{BCE}}^{(k)}(\bar{\mathbf{y}}_{-i}, \mathbf{y}) - \mathcal{L}_{\text{BCE}}^{(k)}(\bar{\mathbf{y}}, \mathbf{y}). \quad (5)$$

A positive value indicates that removing agent i increases the prediction loss, suggesting that the agent provides useful evidence for target k . Since the raw utility scores may vary across agents and prediction targets, we further center the rewards across agents to obtain an advantage signal:

$$A_{i,k} = r_{i,k} - \frac{1}{N} \sum_{j=1}^N r_{j,k}. \quad (6)$$

This advantage signal serves as utility-based supervision for the contribution gate, encouraging the learned aggregation weights to align with each agent’s estimated marginal utility:

$$\mathcal{L}_{\text{pg}} = -\mathbb{E} \left[\sum_{i=1}^N \sum_{k=1}^C A_{i,k} \log W_{i,k} \right]. \quad (7)$$

This objective encourages the contribution gate to consistently assign larger weights to agents that improve predictive performance.

Shapley-based contribution regularization. Although leave-one-out rewards provide a direct estimate of agent utility, they only evaluate contribution under a single exclusion setting and can therefore be unstable in heterogeneous clinical scenarios. To obtain a more robust contribution target, we further adopt the Shapley principle from cooperative game theory [24, 2], which estimates each agent’s average marginal contribution across different collaborating coalitions.

For each agent and prediction target, the Shapley target $\Phi_{i,k}$ is computed as,

$$\Phi_{i,k} \propto \mathbb{E}_{S \subseteq \mathcal{N} \setminus \{i\}} \left[\mathcal{L}_{\text{BCE}}^{(k)}(S, \mathbf{y}) - \mathcal{L}_{\text{BCE}}^{(k)}(S \cup \{i\}, \mathbf{y}) \right]_+, \quad \sum_{i=1}^N \Phi_{i,k} = 1. \quad (8)$$

Intuitively, this formulation measures how much agent i improves prediction performance when added to different subsets of collaborating agents, providing a coalition-aware estimate of contribution importance beyond pairwise or leave-one-out comparisons. The learned contribution gate is then regularized toward this Shapley target:

$$\mathcal{L}_{\text{shap}} = \mathbb{E}[\text{KL}(\Phi \parallel \mathbf{W})]. \quad (9)$$

Remark. We use the term multi-agent in a structural sense: each specialist has a restricted observation space, an agent-specific transformation, a latent state, and an explicit update conditioned on other agents’ states. Unlike standard multi-view fusion, CoMMa refines evidence-specific agent states through inter-agent communication before assigning target-specific contributions to the final clinical decision in heterogeneous clinical decision-making with decentralized information sources.

4 Experiments

4.1 Experimental Settings

Datasets and Implementation Details. Experiments are conducted across four oncology benchmarks: a real-world multidisciplinary tumor board dataset from a large academic healthcare system in North America (HCC Tumorboard; 116 patients), two public oncology benchmarks (MTBBench; 66 patient cases and 573 expert-validated question-answer pairs [28], and LungCure; 999 patients [14]), and an externally annotated clinical dataset from an academic hospital system in East Asia for cross-domain evaluation and interpretability analysis, which we refer to as TUMORBOARDRANK (93 tumor board cases and 276 pairwise option comparisons after filtering single-option cases). Additional details on clinical variables, evidence partitioning, preprocessing, and cohort statistics are provided in Appendix Section A.1. CoMMa is implemented using LangGraph [3] and evaluated with multiple LLM backbones, including Llama3.1-70B-Instruct [12], Qwen2.5-72B [23], and Gemma4- 31B [11]. Unless otherwise specified, experiments use four specialist agents and one round of cross-agent collaborative reasoning with residual scale $\rho = 0.5$; TUMORBOARDRANK uses three specialist agents corresponding to basic profile, clinical tests, and treatment history. HCC experiments use learning rate 2×10^{-5} , 121 epochs, $\lambda_{\text{pg}} = 0.07$, and $\lambda_{\text{shap}} = 1.0$. For MTBBench, we use learning rate 10^{-5} , 31 epochs, $\lambda_{\text{pg}} = 1$, and $\lambda_{\text{shap}} = 1.0$. For LungCure, we use learning rate 5×10^{-5} , 100 epochs, $\lambda_{\text{pg}} = 0.1$, and $\lambda_{\text{shap}} = 2.0$. For TUMORBOARDRANK, we use Gemma4-31B with learning rate 5×10^{-5} , 100 epochs, $\lambda_{\text{pg}} = 0.1$, and $\lambda_{\text{shap}} = 4.0$. We use two NVIDIA A100 80GB GPUs for training each model.

Evaluation Protocol. We report Area Under the ROC Curve (AUC) and Accuracy at a fixed threshold of 0.5. For HCC, AUC and Acc are first computed for each treatment category and then macro-averaged across valid categories. If a validation split contains only one label value for a category, that category is excluded from the HCC macro-AUC calculation. For MTBBench, the progression and recurrence endpoints are evaluated as separate binary tasks. For LungCure, we evaluate six binary staging indicators spanning primary tumor extent (T), regional nodal involvement (N), and distant metastasis (M), and report macro-averaged AUC and Acc across these indicators. For TUMORBOARDRANK, we evaluate candidate management-option ranking using Top-1 Acc, Case Distribution Acc, and Pair Order Acc. Top-1 Acc measures whether the highest-ranked predicted option matches the option with the highest physician consensus; Case Distribution Acc measures whether the full predicted option ordering matches the physician-consensus ordering; and Pair Order Acc measures the fraction of option pairs ordered consistently with physician consensus. All reported summary results are computed over three random seeds, using seeds 1000, 2000, and 3000.

Baseline Methods. We compare CoMMa with single-agent and multi-agent LLM baselines under the same evaluation protocol. The direct single-agent baseline receives the full patient case as one input and outputs a probability for each target without explicit multi-agent interaction. MDAgents Basic [17] is implemented as an adapted medical decision-agent baseline. For HCC, we use the adapted local-LLM MDAgents script with the same HCC label space; for MTBBench, we use the corresponding binary prognosis version. MAC [4] is implemented as a multi-agent consultation baseline in which multiple role-specific doctor agents iteratively estimate the target probability, and the final prediction is obtained from the last consensus round. AI-Hospital [9] is implemented as a collaborative consultation baseline in which several doctor agents provide specialty estimates and a host physician aggregates them into a final probability.

Table 1: Performance comparison on three oncology benchmarks: HCC Tumorboard, Lung Cure, and MTBBench. CoMMA consistently improves predictive performance over single-agent and existing multi-agent baselines across multiple open-source LLM backbones.

Methods	HCC Tumorboard		Lung Cure		MTBBench			
	Treatment Recommendation		TNM Stage Prediction		Progression		Recurrence	
	AUC	Acc	AUC	Acc	AUC	Acc	AUC	Acc
<i>GPT 4.1</i>								
In-context learning	N/A	0.784 $\pm$ 0.007	N/A	0.798 $\pm$ 0.070	N/A	0.485 $\pm$ 0.113	N/A	0.425 $\pm$ 0.086
<i>Llama3.1-70B [12]</i>								
Single-Agent	0.590 $\pm$ 0.066	0.690 $\pm$ 0.064	0.782 $\pm$ 0.061	0.735 $\pm$ 0.044	0.503 $\pm$ 0.001	0.519 $\pm$ 0.004	0.526 $\pm$ 0.018	0.491 $\pm$ 0.011
MDAgents [17]	0.693 $\pm$ 0.040	0.708 $\pm$ 0.019	0.781 $\pm$ 0.051	0.746 $\pm$ 0.048	0.523 $\pm$ 0.010	0.526 $\pm$ 0.032	0.536 $\pm$ 0.013	0.491 $\pm$ 0.023
MAC [4]	0.666 $\pm$ 0.055	0.736 $\pm$ 0.035	0.779 $\pm$ 0.069	0.731 $\pm$ 0.099	0.537 $\pm$ 0.011	0.544 $\pm$ 0.021	0.530 $\pm$ 0.016	0.491 $\pm$ 0.020
AI-Hospital [9]	0.643 $\pm$ 0.038	0.767 $\pm$ 0.007	0.810 $\pm$ 0.048	0.728 $\pm$ 0.061	0.547 $\pm$ 0.032	0.439 $\pm$ 0.026	0.581 $\pm$ 0.008	0.546 $\pm$ 0.016
CoMMA (Ours)	0.711 $\pm$ 0.011	0.795 $\pm$ 0.010	0.837 $\pm$ 0.053	0.797 $\pm$ 0.038	0.756 $\pm$ 0.171	0.666 $\pm$ 0.105	0.711 $\pm$ 0.214	0.606 $\pm$ 0.138
<i>Qwen2.5-72B [23]</i>								
Single-Agent	0.593 $\pm$ 0.072	0.650 $\pm$ 0.035	0.813 $\pm$ 0.032	0.713 $\pm$ 0.069	0.517 $\pm$ 0.015	0.543 $\pm$ 0.010	0.502 $\pm$ 0.006	0.436 $\pm$ 0.004
MDAgents [17]	0.602 $\pm$ 0.080	0.710 $\pm$ 0.024	0.803 $\pm$ 0.034	0.750 $\pm$ 0.039	0.517 $\pm$ 0.008	0.544 $\pm$ 0.020	0.501 $\pm$ 0.023	0.437 $\pm$ 0.010
MAC [4]	0.689 $\pm$ 0.070	0.639 $\pm$ 0.044	0.799 $\pm$ 0.050	0.761 $\pm$ 0.057	0.531 $\pm$ 0.009	0.543 $\pm$ 0.020	0.525 $\pm$ 0.006	0.473 $\pm$ 0.004
AI-Hospital [9]	0.637 $\pm$ 0.100	0.727 $\pm$ 0.034	0.827 $\pm$ 0.079	0.792 $\pm$ 0.090	0.542 $\pm$ 0.015	0.544 $\pm$ 0.002	0.517 $\pm$ 0.001	0.455 $\pm$ 0.010
CoMMA (Ours)	0.700 $\pm$ 0.014	0.750 $\pm$ 0.032	0.844 $\pm$ 0.020	0.802 $\pm$ 0.044	0.809 $\pm$ 0.090	0.666 $\pm$ 0.053	0.845 $\pm$ 0.107	0.576 $\pm$ 0.139
<i>Gemma4-31B [11]</i>								
Single-Agent	0.625 $\pm$ 0.058	0.693 $\pm$ 0.047	0.802 $\pm$ 0.063	0.815 $\pm$ 0.061	0.556 $\pm$ 0.024	0.491 $\pm$ 0.045	0.534 $\pm$ 0.017	0.491 $\pm$ 0.033
MDAgents [17]	0.645 $\pm$ 0.014	0.718 $\pm$ 0.021	0.826 $\pm$ 0.053	0.817 $\pm$ 0.064	0.590 $\pm$ 0.022	0.543 $\pm$ 0.018	0.616 $\pm$ 0.030	0.564 $\pm$ 0.056
MAC [4]	0.645 $\pm$ 0.067	0.719 $\pm$ 0.039	0.822 $\pm$ 0.044	0.827 $\pm$ 0.059	0.619 $\pm$ 0.040	0.597 $\pm$ 0.014	0.597 $\pm$ 0.031	0.564 $\pm$ 0.017
AI-Hospital [9]	0.640 $\pm$ 0.028	0.747 $\pm$ 0.036	0.791 $\pm$ 0.105	0.805 $\pm$ 0.081	0.616 $\pm$ 0.044	0.614 $\pm$ 0.019	0.623 $\pm$ 0.014	0.583 $\pm$ 0.022
CoMMA (Ours)	0.680 $\pm$ 0.028	0.758 $\pm$ 0.027	0.841 $\pm$ 0.048	0.830 $\pm$ 0.073	0.905 $\pm$ 0.083	0.697 $\pm$ 0.105	0.911 $\pm$ 0.077	0.666 $\pm$ 0.139

Table 2: Ablation study on HCC Tumorboard treatment recommendation.

Eqn. (2)	$\mathcal{L}_{pg}$	$\mathcal{L}_{shap}$	Llama3.1-70B		Qwen2.5-72B	
			AUC	Acc	AUC	Acc
✓	✓		0.706 $\pm$ 0.007	0.688 $\pm$ 0.068	0.682 $\pm$ 0.015	0.738 $\pm$ 0.004
✓		✓	0.691 $\pm$ 0.015	0.659 $\pm$ 0.042	0.691 $\pm$ 0.031	0.728 $\pm$ 0.015
	✓	✓	0.692 $\pm$ 0.012	0.741 $\pm$ 0.056	0.681 $\pm$ 0.024	0.722 $\pm$ 0.046
✓	✓	✓	0.711 $\pm$ 0.011	0.795 $\pm$ 0.010	0.700 $\pm$ 0.014	0.750 $\pm$ 0.032
1. Replace learned weights with uniform dist.			0.693 $\pm$ 0.008	0.683 $\pm$ 0.072	0.625 $\pm$ 0.023	0.661 $\pm$ 0.055
2. Sampled-coalition Shapley approximation.			0.689 $\pm$ 0.011	0.717 $\pm$ 0.049	0.698 $\pm$ 0.013	0.725 $\pm$ 0.029
3. Use centralized input.			0.691 $\pm$ 0.006	0.734 $\pm$ 0.055	0.692 $\pm$ 0.008	0.613 $\pm$ 0.086

4.2 Main Results

Comparison on different oncology benchmarks. Table 1 compares CoMMA with single-agent and existing multi-agent baselines across HCC Tumorboard, Lung Cure, and MTBBench. CoMMA consistently achieves the best overall performance across benchmarks and LLM backbones. On HCC Tumorboard, CoMMA obtains the highest treatment recommendation accuracy under all three backbones, improving Llama3.1-70B from 0.690 to 0.795 and Qwen2.5-72B from 0.650 to 0.750 over the single-agent baseline. On Lung Cure, CoMMA also improves TNM stage prediction, achieving the best accuracy with Qwen2.5-72B (0.802) and Gemma-31B (0.830). The largest gains appear on MTBBench, where CoMMA substantially improves progression and recurrence prediction. These results show that CoMMA generalizes across real-world and public oncology benchmarks while consistently improving predictive performance.

Comparison on various LLM backbones. CoMMA shows consistent gains across Llama3.1-70B, Qwen2.5-72B, and Gemma-31B, indicating that the framework is not tied to a specific backbone. With Llama3.1-70B, CoMMA improves HCC treatment recommendation AUC from 0.590 to 0.711 and accuracy from 0.690 to 0.795 over the single-agent baseline. It also improves MTBBench progression AUC from 0.503 to 0.756 and recurrence AUC from 0.526 to 0.711. Similar trends are observed with Qwen2.5-72B, where CoMMA achieves the best results among open-source baselines across all tasks, including Lung Cure accuracy of 0.802 and MTBBench recurrence AUC of 0.845. With Gemma-31B, CoMMA yields especially large improvements on MTBBench, increasing progression AUC from 0.556 to 0.905 and recurrence AUC from 0.534 to 0.911 over the single-agent baseline. Overall, these results show that decentralized specialist encoding and contribution-aware aggregation provide robust improvements across different LLM families and model scales.

4.3 Experimental Analysis




Figure 3: Comparison of AUC/Acc across different methods using the medical-related Meditron-70B backbone [6] on multiple clinical evaluation tasks.

To further investigate the behavior of CoMMA beyond the quantitative performance improvements reported above, we conduct additional analyses to better understand how the proposed framework achieves its gains, whether the learned contribution patterns are clinically meaningful, and how well the framework generalizes across different model settings and medical foundation backbones. Specifically, the following analyses are organized around three key questions.

Question 1: How does each component of CoMMA contribute to performance? Table 2 reports ablation results on HCC treatment recommendation. Removing either contribution-learning objective degrades performance, showing that $\mathcal{L}_{pg}$ and $\mathcal{L}_{shap}$ provide complementary supervision for the contribution gate. We further analyze the effect of contribution-aware aggregation. Replacing the learned contribution weights with uniform averaging degrades both AUC and Acc, showing that patient-specific agent weighting is important for effective multi-agent collaboration. In addition, replacing exact Shapley computation with Monte Carlo approximation leads to lower performance, suggesting that accurate coalition-aware contribution estimation improves the stability of contribution learning. Finally, using centralized input degrades performance, indicating the benefit of decentralized data streams. Overall, the ablation results demonstrate that both contribution-aware weighting and Shapley-based regularization are important components of the proposed CoMMA algorithm.

Question 2: What if other multi-agent methods also adopt finetuning? To examine whether CoMMA’s improvement is simply due to supervised adaptation, we introduce fine-tuned variants of existing SOTA multi-agent baselines, AI-Hospital-FT. All fine-tuned baselines use the same backbone, data split, prediction labels, training objective, and evaluation protocol as CoMMA. As shown in Table 3, finetuning improves these baselines over their prompt-only versions, but CoMMA still achieves the best overall performance. This indicates that CoMMA’s gains are not merely a result of finetuning, but are also attributable to decentralized evidence specialization, latent cross-agent communication, and contribution-aware aggregation. Other finetuned baselines are in the A.4.

Table 3: Fine-tuned baselines (mean of 3 seeds).

HCC Tumorboard	Llama		Qwen		Gemma	
	AUC	Acc	AUC	Acc	AUC	Acc
AI-Hospital-FT	0.676	0.753	0.684	0.738	0.607	0.751
CoMMA	0.711	0.795	0.700	0.750	0.680	0.758

Question 3: Does CoMMA remain effective with medical foundation models? As shown in Fig. 3, we evaluate CoMMA on Meditron-70B [6], where it consistently delivers improvements over strong domain-specific LLMs. CoMMA achieves higher AUC and accuracy across all tasks, demonstrating its effectiveness even when built on top of medical-specialized backbones. These results indicate that CoMMA provides complementary gains beyond model pretraining and remains robust across different backbone choices and diverse clinical evaluation settings.

Question 4: Does CoMMA provide clinically meaningful contribution attribution? We conduct this analysis on TUMORBOARDRANK, an externally annotated tumor board option-ranking dataset with physician-consensus preferences. As shown in Fig. 4, we compare CoMMA with Single-Agent and AI-Hospital, the strongest overall baseline. Using Gemma4-31B, CoMMA improves Top-1 Acc, Case Distribution Acc, and Pair Order Acc over both baselines, suggesting better recovery of physician-consensus rankings. In the representative case, CoMMA produces a normalized ranking distribution that better follows physician consensus, while the baselines over-weight lower-ranked alternatives. Fig. 5 further analyzes the same case. Single-Agent view confidence is computed from




Figure 4: Performance and representative case analysis on TUMORBOARDRANK using Gemma4-31B. Left: overall comparison. Right: normalized option-ranking scores for a representative case, with physician consensus as the reference distribution.




Figure 5: View-weight and pairwise-alignment analysis for a representative TUMORBOARDRANK case using Gemma4-31B. (a) View-level confidence and learned CoMMA weights across evidence streams. (b) Pairwise alignment with physician-consensus option ordering, where sign indicates agreement and magnitude indicates confidence.

frozen Gemma4-31B view-level logit margins, whereas CoMMA weights are learned by the fusion module. CoMMA assigns larger weights to clinically informative streams, such as clinical tests and treatment history, and down-weights the less informative basic profile view, indicating learned evidence reweighting beyond raw view confidence. Although CoMMA makes one more pairwise error than the view-level Gemma4 baseline, this error has low confidence, whereas the baseline makes a high-confidence error. This explains why CoMMA recovers the correct case-level distribution in Fig. 4, while the baseline assigns excessive mass to a lower-ranked option.

5 Conclusion and Limitation

In this work, we propose CoMMA, a contribution-aware medical multi-agent framework that replaces prompt-based role interaction with decentralized specialist modeling and structured contribution learning. By combining evidence-specific specialist agents, deterministic cross-agent collaboration, and Shapley-regularized contribution aggregation, CoMMA provides improved predictive performance and explicit agent-level attribution. Experiments across multiple oncology benchmarks demonstrate consistent gains over single-agent and existing multi-agent baselines under different open-source LLM backbones. In addition, the decentralized design of CoMMA better supports privacy-sensitive and resource-constrained clinical deployment settings by avoiding full-context sharing and expensive cloud-based inference. Future work will extend CoMMA beyond oncology benchmarks to broader clinical domains and more heterogeneous healthcare settings. We also plan to investigate finer-grained contribution estimation and representation disentanglement to better model complex interactions among correlated clinical evidence streams. Finally, extending contribution-aware multi-agent reasoning to open-ended clinical decision-making scenarios, including ambiguous outcomes and free-form clinical reasoning, represents an important direction for future research.

References

- [1] Mohammad Almansoori, Komal Kumar, and Hisham Cholakkal. Medagentsim: Self-evolving Multi-agent Simulations for Realistic Clinical Interactions. In *International Conference on Medical Image Computing and Computer-Assisted Intervention*, pages 362–372, 2025.
- [2] Daniel Beechey, Thomas M. S. Smith, and Özgür Şimşek. Explaining Reinforcement Learning with Shapley Values. In *International Conference on Machine Learning*, pages 2003–2014, 2023.
- [3] Harrison Chase. Langchain, 2022.
- [4] Xi Chen, Huahui Yi, Mingke You, WeiZhi Liu, Li Wang, Hairui Li, Xue Zhang, Yingman Guo, Lei Fan, Gang Chen, et al. Enhancing Diagnostic Capability with Multi-agents Conversational Large Language Models. *NPJ digital medicine*, 8(1):159, 2025.
- [5] Xiaolan Chen, Jiayang Xiang, Shanfu Lu, Yexin Liu, Mingguang He, and Danli Shi. Evaluating Large Language Models and Agents in Healthcare: Key Challenges in Clinical Applications. *Intelligent Medicine*, 5(2):151–163, 2025.
- [6] Zeming Chen, Ehsaneddin Asgari, Seyed Mohammad Mousavi, et al. Meditron: Scaling medical pretraining for large language models. *arXiv preprint arXiv:2311.16079*, 2023.
- [7] Christophe Dutang, Hansjoerg Albrecher, and Stéphane Loisel. Competition Among Non-life Insurers under Solvency Constraints: A Game-theoretic Approach. *European Journal of Operational Research*, 231(3):702–711, 2013.
- [8] Adibvafa Fallahpour, Jun Ma, Alif Munim, Hongwei Lyu, and Bo Wang. Medrax: Medical Reasoning Agent for Chest X-ray. In *International Conference on Machine Learning*, pages 15661–15676, 2025.
- [9] Zhihao Fan, Lai Wei, Jialong Tang, Wei Chen, Wang Siyuan, Zhongyu Wei, and Fei Huang. AI Hospital: Benchmarking Large Language Models in a Multi-agent Medical Interaction Simulator. In *International Conference on Computational Linguistics*, pages 10183–10213, 2025.
- [10] Dyke Ferber, Omar SM El Nahhas, Georg Wölflein, Isabella C Wiest, Jan Clusmann, Marie-Elisabeth Leßmann, Sebastian Foersch, Jacqueline Lammert, Maximilian Tschochohei, Dirk Jäger, et al. Development and validation of an Autonomous Artificial Intelligence Agent for Clinical Decision-making in Oncology. *Nature cancer*, pages 1–13, 2025.
- [11] Google DeepMind. Gemma 4 31b it. Hugging Face model card, 2026. Accessed: 2026-05-06.
- [12] Aaron Grattafiori, Abhimanyu Dubey, Abhinav Jauhri, Abhinav Pandey, Abhishek Kadian, Ahmad Al-Dahle, Aiesha Letman, Akhil Mathur, Alan Schelten, Alex Vaughan, et al. The Llama 3 Herd of Models. *arXiv preprint arXiv:2407.21783*, 2024.
- [13] Xudong Han, Xianglun Gao, Xiaoyi Qu, and Zhenyu Yu. Multi-Agent Medical Decision Consensus Matrix System: An Intelligent Collaborative Framework for Oncology MDT Consultations. *arXiv preprint arXiv:2512.14321*, 2025.
- [14] Fangyu Hao, Jiayu Yang, Yifan Zhu, Zijun Yu, Qicen Wu, Wang Yunlong, Jiawei Li, Yulin Liu, Xu Zeng, Guanting Chen, et al. Lungcure: Benchmarking multimodal real-world clinical reasoning for precision lung cancer diagnosis and treatment. *arXiv preprint arXiv:2604.06925*, 2026.
- [15] Edwin Ho, Arvind Rajagopalan, Alex Skvortsov, Sanjeev Arulampalam, and Mahendra Piraveenan. Game Theory in Defence Applications: A Review. *Sensors*, 22(3):1032, 2022.
- [16] Shreya Johri, Jaehwan Jeong, Benjamin A Tran, Daniel I Schlessinger, Shannon Wongvibulsin, Leandra A Barnes, Hong-Yu Zhou, Zhuo Ran Cai, Eliezer M Van Allen, David Kim, et al. An Evaluation Framework for Clinical Use of Large Language Models in Patient Interaction Tasks. *Nature medicine*, 31(1):77–86, 2025.

- [17] Yubin Kim, Chanwoo Park, Hyewon Jeong, Yik S Chan, Xuhai Xu, Daniel McDuff, Hyeonhoon Lee, Marzyeh Ghassemi, Cynthia Breazeal, and Hae W Park. MDagents: An Adaptive Collaboration of LLMs for Medical Decision-making. *Advances in Neural Information Processing Systems*, pages 79410–79452, 2024.
- [18] Marc Lanctot, Vinicius Zambaldi, Audrūnas Gruslys, Angeliki Lazaridou, Karl Tuyls, Julien Pérolat, David Silver, and Thore Graepel. A Unified Game-theoretic Approach to Multi-agent Reinforcement Learning. In *Advances in Neural Information Processing Systems*, page 4193–4206, 2017.
- [19] Chng Wei Lau, Daniel Catchpoole, Simeon Simoff, Dongmo Zhang, and Quang Vinh Nguyen. A Game-theoretical Approach to Clinical Decision Making with Immersive Visualisation. *Applied Sciences*, 13(18):10178, 2023.
- [20] Francisco V Mendonça, Margarida Catalao-Lopes, Rui Tato Marinho, and Jose Rui Figueira. Improving Medical Decision-making with a Management Science Game Theory Approach to Liver Transplantation. *Omega*, 94:102050, 2020.
- [21] Simon Parsons and Michael Wooldridge. Game Theory and Decision Theory in Multi-agent Systems. *Autonomous Agents and Multi-Agent Systems*, 5(3):243–254, 2002.
- [22] Vivek Patkar, Dionisio Acosta, Tim Davidson, Alison Jones, John Fox, and Mohammad Keshtgar. Cancer Multidisciplinary Team Meetings: Evidence, Challenges, and the Role of Clinical Decision Support Technology. *International Journal of Breast Cancer*, 2011(1):831605, 2011.
- [23] Alibaba Group Qwen Team. Qwen2.5 technical report. *arXiv preprint arXiv:2407.10671*, 2024.
- [24] LS Shapley. A Value For n-Person Games’. *Contributions to the Theory of Games*, (28):307, 1953.
- [25] Xiangru Tang, Daniel Shao, Jiwoong Sohn, Jiapeng Chen, Jiayi Zhang, Jinyu Xiang, Fang Wu, Yilun Zhao, Chenglin Wu, Wenqi Shi, et al. Medagentsbench: Benchmarking Thinking Models and Agent Frameworks for Complex Medical Reasoning. *arXiv preprint arXiv:2503.07459*, 2025.
- [26] Xiangru Tang, Anni Zou, Zhuosheng Zhang, Ziming Li, Yilun Zhao, Xingyao Zhang, Arman Cohan, and Mark Gerstein. Medagents: Large Language Models as Collaborators for Zero-shot Medical Reasoning. In *Findings of the Association for Computational Linguistics*, pages 599–621, 2024.
- [27] Cath Taylor, Alastair J Munro, Rob Glynn-Jones, Clive Griffith, Paul Trevatt, Michael Richards, and Amanda J Ramirez. Multidisciplinary Team Working in Cancer: What is the Evidence? *British Medical Journal*, 340:743–745, 2010.
- [28] Kiril Vasilev, Alexandre Misrahi, Eeshaan Jain, Phil F Cheng, Petros Liakopoulos, Olivier Michielin, Michael Moor, and Charlotte Bunne. MTBBench: A Multimodal Sequential Clinical Decision-Making Benchmark in Oncology. *Advances in Neural Information Processing Systems Datasets and Benchmarks Track*, 2025.
- [29] John Von Neumann and Oskar Morgenstern. Theory of Games and Economic Behavior: 60th Anniversary Commemorative Edition. In *Theory of Games and Economic Behavior*. Princeton University Press, 2007.
- [30] Ziyue Wang, Junde Wu, Linghan Cai, Chang Han Low, Xihong Yang, Qiakuan Li, and Yueming Jin. MedAgent-Pro: Towards Evidence-Based Multi-Modal Medical Diagnosis via Reasoning Agentic Workflow. *arXiv preprint arXiv:2503.18968*, 2025.
- [31] Weitong Zhang, Mengyun Qiao, Chengqi Zang, Steven Niederer, Paul M Matthews, Wenjia Bai, and Bernhard Kainz. Multi-Agent Reasoning for Cardiovascular Imaging Phenotype Analysis. In *International Conference on Medical Image Computing and Computer-Assisted Intervention*, pages 429–439, 2025.

- [32] Yucheng Zhou, Lingran Song, and Jianbing Shen. MAM: Modular Multi-Agent Framework for Multi-Modal Medical Diagnosis via Role-Specialized Collaboration. *arXiv preprint arXiv:2506.19835*, 2025.
- [33] James Zou and Eric J Topol. The Rise of Agentic AI Teammates in Medicine. *The Lancet*, 405(10477):457, 2025.

A Appendix

A.1 Dataset Details.

A.1.1 HCC Tumorboard

The HCC Tumorboard dataset comprises 116 patients diagnosed with primary Hepatocellular Carcinoma (HCC) at a large tertiary academic hospital in North America. The study was conducted under institutional IRB approval. The cohort includes adult patients with confirmed hepatocellular carcinoma, no concurrent malignancies, and multidisciplinary tumor board review during the study period. Each case was reviewed by a multidisciplinary tumor board to establish the consensus treatment recommendation, which serves as the ground-truth label. Cases without recommendations in all treatment categories were excluded. We adopt a 75/25% train-test split. The ground-truth label is defined over eight discrete treatment options: (A) transcatheter arterial chemoembolization (TACE), (B) ablation, primarily microwave ablation (MWA), (C) radioembolization/ selective internal radiation therapy (SIRT), (D) radiotherapy, (E) surgical resection, (F) liver transplant, (G) chemotherapy, and (H) palliative care. Each instance contains 24 multimodal clinical variables represented in textual format, extracted from longitudinal clinical records and MRI reports. An exemplar case illustrating the HCC Tumorboard data construction is provided in Table 4.

Table 4: HCC Tumorboard Data Formation.

Decentralized Data				
	x_1 MRI imaging features	x_2 OPTN [†] information	x_3 Performance score	x_4 Laboratory data
Context example	Number of tumors: 4.0	Number of OPTN 5A tumors: 0	Child-Pugh score: A	Encephalopathy: 0
	Size of largest tumor (cm): 2.6	Number of OPTN 5B tumors: 2	ECOG [‡] score: 1	Ascites: 0
	Location largest (segment): 8	Number of OPTN 5X tumors: 0	MELD [§] score: 13.0	Bilirubin: 0.6
	Vascular invasion: 0	Number of OPTN 5T tumors: 0		Albumin: 4.8
	Extrahepatic spread: 0			INR: 1.1
	Thrombus (portal vein): 0			AFP: 5.0
	⋮			⋮

[†]OPTN: Organ Procurement & Transplantation Network, [‡]ECOG: Eastern Cooperative Oncology Group Performance, [§]MELD: Model for End-stage Liver Disease

A.1.2 MTBBench

MTBBench [28] is an agentic benchmark designed to evaluate molecular tumor board-style reasoning that requires integrating multimodal evidence and longitudinal patient context. It contains 66 patient cases and 573 expert-validated question-answer pairs across two tracks. The multimodal track includes 26 head and neck cancer cases, with approximately 40 modality-specific files per patient, including H&E slides, IHC images, and hematology reports, yielding 390 questions. The longitudinal track includes 40 cases with approximately five structured files per patient and 183 questions focused on time-dependent outcomes, including recurrence and progression. In our experiments, we focus on prognosis prediction tasks for tumor recurrence and progression. Each sample is formulated as a paired clinical question and binary endpoint label. We adopt an 80/20 % train-test split for MTBBench. An exemplar case illustrating the MTBBench data construction is provided in Table 5.

Table 5: MTBBench Data Formation.

Decentralized Data				
	x_1 Specimen metadata	x_2 Somatic mutations	x_3 Copy number alterations	x_4 Structural variants
Context example	Colon Adenocarcinoma	TP53 p.C242F	ERBB2 gain (Value: 2.0)%	CTNNB1 Splice Site
	Primary (Sigmoid Colon)	FANCA p.V750M	CDK12 gain (Value: 2.0)	deletion (c.18_242-37del)
	Tumor Purity: 20.0%	CDK12 p.S238*	⋮	⋮
	MSI Type: Stable	⋮	⋮	⋮
	⋮	⋮	⋮	⋮

A.1.3 LungCure

LungCure [14] is a lung cancer staging benchmark designed to evaluate clinical reasoning from longitudinal OCR-derived patient records. It contains 999 patients and We adopt an 80/20 % train-test split. In our experiments, we focus on six binary staging indicators spanning primary tumor

extent (T), regional nodal involvement (N), and distant metastasis (M): T2a, T1c, N0, N2, M0, and M1c. Each sample is formulated as a patient record paired with a binary TNM staging label. We partition each record into TNM-oriented evidence streams, including primary tumor evidence, nodal evidence, metastasis evidence, and clinical history. An exemplar case illustrating the LungCure data construction is provided in Table 6.

Table 6: LungCure Data Formation.

	Decentralized Data			
	x_1 Primary tumor evidence	x_2 Regional nodal evidence	x_3 Distant metastasis evidence	x_4 Clinical history
Context example	Right upper-lobe solid nodule Size: 3.1×3.3×2.7 cm SUVmax: 8.1 Spiculation and pleural traction ⋮	Right hilar lymph nodes enlarged Right paratracheal lymph nodes Increased FDG uptake SUVmax: 5.9 ⋮	No definite distant metastasis No abnormal liver uptake No pelvic or retroperitoneal nodes T4 bone island, favored benign ⋮	Smoking history over 30 years Family history of ovarian cancer PET/CT for systemic assessment Thoracic surgery outpatient referral ⋮

A.1.4 TUMORBOARDRANK

TUMORBOARDRANK is an externally annotated tumor board option-ranking dataset for evaluating cross-domain clinical decision ranking and interpretability. It contains 93 tumor board cases after filtering single-option cases, yielding 276 pairwise option comparisons. Each case consists of a refined clinical case summary, physician-consensus preferences over candidate management options, and the corresponding option descriptions. We use a case-level temporal split, with 73 cases for training and 20 cases for testing. For CoMMA, each case is partitioned into three evidence streams: basic profile, clinical tests, and treatment history. An exemplar case illustrating the TUMORBOARDRANK data construction is provided in Table 7.

Table 7: TUMORBOARDRANK Data Formation.

	Decentralized Data		
	x_1 Basic profile	x_2 Clinical tests	x_3 Treatment history
Context example	37-year-old man Laryngeal squamous cell carcinoma ECOG performance status: 0 No chronic high-grade toxicity ⋮	Isolated nodal recurrence Salvage neck dissection 1 of 10 lymph nodes positive Extranodal extension present ⋮	Prior definitive chemoradiation 69.96 Gy in 33 fractions 56.1 Gy elective nodal irradiation Cisplatin cumulative dose: 200 mg/m ² ⋮

A.2 Detailed Shapley Computation.

A.2.1 Comparison to Advantage Vector

Unlike the advantage vector A_i , which only considers the marginal impact of removing agent i from the full coalitions $\mathcal{N}$, Shapley value evaluates the contribution of agent i across a diverse set of sub-coalitions $S \subseteq \mathcal{N} \setminus \{i\}$, of varying cardinalities. Consequently, the resulting Shapley matrix Φ captures an expected marginal contribution that explicitly accounts for inter-agent interactions and dependencies, rather than being dominated by sample-specific or coalition-dependent fluctuations.

A.3 Comparison on Computational Cost.

We compare computational complexity and cost across trainable baselines, single-agent in-context learning, role-based multi-agent systems, and our locally fine-tunable multi-agent approach in Table 8. Latency and inference token usage are averaged over 30 samples from the HCC Tumorboard dataset. Our results show that CoMMA is a cost-effective method, achieving lower latency under a free-inference setting while delivering superior performance.

A.4 Fine-Tuned Multi-Agent Baselines

To assess whether CoMMA’s gains can be explained solely by supervised fine-tuning, we construct fine-tuned variants of representative multi-agent baselines. These baselines use the same LLM backbone, train-test split, prediction labels, supervision objective, and evaluation protocol as CoMMA.

Table 8: Computational Complexity and cost Comparison on HCC Tumorboard Dataset.

Methods	Trainable Baselines	Single-Agent In-context Learning	Role-based Multi-Agents	Locally Fine-tunable Multi-Agents
	CatBoost	GPT 4.1	MDAgents	CoMMa
Computational Complexity	0.048 MFLOPs	Unreleased	Unreleased	280 TFLOPs
Total Trainable Parameters	0.512 M	None	None	16.8 M
Latency (per input)	0.116 ms	4.2 s	79.2 s	1.1 s
Inference Tokens (chargeable)	None	20,878	23,254	None

Table 9: Comparison with fine-tuned multi-agent baselines on HCC Tumorboard. Results are averaged over 3 random seeds.

HCC	Llama		Qwen		Gemma	
	AUC	Acc	AUC	Acc	AUC	Acc
MAC	0.656	0.780	0.690	0.738	0.650	0.739
MDAgents	0.676	0.776	0.685	0.741	0.626	0.731
AI-Hospital	0.676	0.753	0.684	0.738	0.607	0.751
CoMMa	0.711	0.795	0.700	0.750	0.680	0.758

The main paper reports AI-Hospital-FT, while additional fine-tuned baselines are summarized in Tabel 9. For each baseline, we preserve its original multi-agent organization whenever possible and add a supervised prediction head trained on the task-specific labels. The frozen LLM encoder is used to obtain case-level or agent-level representations, and the trainable head is optimized with the same binary cross-entropy objective used by CoMMa. This setup controls for the effect of task-specific supervision while retaining each baseline’s original agent structure.

A.5 Detailed Class-wise Performance Comparison on HCC Treatments.

A.6 Additional Response Comparison.

A.6.1 HCC Tumorboard

We further provide agentic framework response comparison on HCC Tumorboard dataset in Figure 6 and Figure 7. Whereas single-agent in-context learning and role-based multi-agent methods often yield verbose yet clinically inconsistent rationales, CoMMa provides quantitative attribution of agent contributions within a structured decision framework, resulting in superior predictive performance.

A.6.2 MTBBench

We provide a comparison of agentic framework responses on the MTBBench dataset. Specifically, we present a representative sample from each tumor progression tasks in Figure 8 and tumor recurrence prediction tasks in Figure 9. We observe that despite the extensive reasoning produced by both single-agent in-context learning and role-based multi-agent frameworks, their predictive accuracy remains significantly inferior to our proposed method.

Clinical Data	GT	(a) Single-Agent In-context Learning	(b) Role-based Multi-Agents	(c) CoMMA (Ours)																											
Question: You are an expert Oncologist AI assistant. Analyze the following <Clinical Data> for a patient and recommend the most appropriate therapeutic recommendations from the provided <Options>.																															
Image-specific data - Number of tumors:1 - Size of Largest Tumor (CM):2.0 - Location Largest (Segment):8 - Segment 1:0 - Segment 2:0 - Segment 3:0 - Segment 4A:0 - Segment 4B:0 - Segment 5:0 - Segment 6:0 - Segment 7:0 - Segment 8:1 - Size second (CM):- - Size third (CM):- - Vascular invasion:0 - Extra hepatic Spread:0 - Thrombus (Portal Vein):0 Transplant Network-specific data - Number of OPTN 5A Tumors:0 - Number of OPTN 5B Tumors:0 - Number of OPTN 5X Tumors:0 - Number of OPTN 5T Tumors:0 Performance-specific data - Child Pugh Score:- - MELD Score:- - ECOG Score: 0 Laboratory-specific data - Encephalopathy:0 - Ascites:0 - Bilirubin:0.3 - Albumin:4.0 - INR:1.1 - AFP:2.2 Options (A) TACE (B) Ablation (C) Radioembolization (D) Radiotherapy (E) Resection (F) Transplant (G) Chemo (H) Palliative	(E) Resection	<Prediction> [(B) Ablation, (E) Resection] **Reasoning:** - The patient has a solitary HCC (Number of tumors: 1), size 2.0 cm, located in segment 8. - No vascular invasion, no extrahepatic spread, no portal vein thrombus. - Excellent performance status (ECOG 0), no encephalopathy, no ascites. - Liver function is well preserved (Bilirubin 0.3, Albumin 4.0, INR 1.1). - AFP is low (2.2). **In-context learning from dataset:** - Cases 83 and 11 have nearly identical features (solitary 2.0 cm tumor, segment 8, no invasion, preserved liver function, ECOG 0-1), both recommended for ablation and/or resection. - Current guidelines (AASLD, EASL) recommend ablation or resection for solitary tumors <3 cm, good performance status, and well-preserved liver function. **Summary:** Both percutaneous ablation and surgical resection are appropriate and potentially curative options. The choice depends on technical feasibility, patient preference, and comorbidity.	**Case Summary:** - "Number of tumors:" 1 - "Size of largest tumor:" 2.0 cm - "Location:" Segment 8 - "No vascular invasion, extrahepatic spread, or portal vein thrombus" - "Performance status (ECOG):" 0 (fully active) - "No ascites or encephalopathy" - "Liver function:" Bilirubin 0.3, Albumin 4.0, INR 1.1 (all normal) - "AFP:" 2.2 (not elevated) - "Child-Pugh and MELD scores not provided, but clinical and lab data suggest well-compensated liver function (likely Child-Pugh A)" - "No evidence of advanced disease or poor functional status" **Interpretation:** This patient has a single, small hepatocellular carcinoma (HCC) in segment 8, with preserved liver function and excellent performance status. There is no evidence of vascular invasion, extrahepatic spread, or portal vein thrombus. **Treatment Decision:** **Curative options are preferred.** According to international guidelines (AASLD, EASL, BCLC), for a single HCC <2.0 cm in a patient with well-compensated liver function and good performance status, the following are considered: 1. **Surgical Resection (E):** - Indicated for solitary tumors in patients with preserved liver function and no portal hypertension. - This patient fits the criteria: single tumor, normal labs, no ascites, no encephalopathy, ECOG 0. - "Resection is the preferred option." 2. **Ablation (B):** - For very early HCC (<2.0 cm), ablation (e.g., radiofrequency or microwave) is an alternative if resection is not feasible due to comorbidities or technical reasons. - In this case, ablation is a valid alternative, especially if surgery is contraindicated. 3. **Transplant (F):** - Reserved for patients with multifocal disease, poor liver function, or when resection/ablation is not possible. - This patient does not require transplant at this stage. 4. **Other options (G, C, H, A, D):** - Chemo (G), radioembolization (C), arterial therapy (A), radiotherapy (D), and palliative care (H) are not first-line for a single, small HCC in a patient with good liver function and performance status. **Final Recommendation:** **Primary Recommendation:** (E) Resection : Surgical resection is the treatment of choice for this patient. **Alternative (if resection is not feasible):** (B) Ablation : Percutaneous ablation is an excellent alternative. **Other options are not indicated at this stage.** **Summary Table:** <table><tr><th>Option</th><th>Indication in this case</th><th>Recommendation</th></tr><tr><td>(E) Resection</td><td>Yes</td><td>First choice</td></tr><tr><td>(B) Ablation</td><td>Yes (if not surgical)</td><td>Alternative</td></tr><tr><td>(F) Transplant</td><td>No</td><td>Not indicated</td></tr><tr><td>(G) Chemo</td><td>No</td><td>Not indicated</td></tr><tr><td>(C) Radioembolization</td><td>No</td><td>Not indicated</td></tr><tr><td>(A) TACE</td><td>No</td><td>Not indicated</td></tr><tr><td>(D) Radiotherapy</td><td>No</td><td>Not indicated</td></tr><tr><td>(H) Palliative</td><td>No</td><td>Not indicated</td></tr></table>	Option	Indication in this case	Recommendation	(E) Resection	Yes	First choice	(B) Ablation	Yes (if not surgical)	Alternative	(F) Transplant	No	Not indicated	(G) Chemo	No	Not indicated	(C) Radioembolization	No	Not indicated	(A) TACE	No	Not indicated	(D) Radiotherapy	No	Not indicated	(H) Palliative	No	Not indicated	Result: (Logit / Cutoff) (E) Resection (86% / 79%) (B) Ablation (85% / 64%) Agent's Contribution
Option	Indication in this case	Recommendation																													
(E) Resection	Yes	First choice																													
(B) Ablation	Yes (if not surgical)	Alternative																													
(F) Transplant	No	Not indicated																													
(G) Chemo	No	Not indicated																													
(C) Radioembolization	No	Not indicated																													
(A) TACE	No	Not indicated																													
(D) Radiotherapy	No	Not indicated																													
(H) Palliative	No	Not indicated																													

Figure 6: Additional agentic framework response comparison on HCC Tumorboard dataset - #1. (a) Single-agent in-context learning (GPT-4.1), (b) Role-based multi-agent framework (MDAgents-Advanced), and (c) CoMMA. For the role-based multi-agent, intermediate discussions are omitted, and only the final consensus is visualized. For CoMMA, class-wise logits and cutoff thresholds are transformed into percentiles.

Clinical Data	GT	(a) Single-Agent In-context Learning	(b) Role-based Multi-Agents	(c) CoMMA (Ours)
Question: You are an expert Oncologist AI assistant. Analyze the following <Clinical Data> for a patient and recommend the most appropriate therapeutic recommendations from the provided <Options>.				
Image-specific data - Number of tumors:2.0 - Size of Largest Tumor (CM):7.9 - Location Largest (Segment):7,8 - Segment 1:0 - Segment 2:0 - Segment 3:0 - Segment 4A:0 - Segment 4B:0 - Segment 5:0 - Segment 6:0 - Segment 7:1 - Segment 8:1 - Size Second (CM):1.2 - Size Third (CM): - Vascular Invasion:1 - Extra hepatic Spread:1 - Thrombus (Portal Vein):0 ... Transplant Network-specific data - Number of OPTN 5A Tumors:1 - Number of OPTN 5B Tumors:0 - Number of OPTN 5X Tumors:0 - Number of OPTN 5T Tumors:0 Performance-specific data - Child Pugh Score:- - MELD Score:- - ECOG Score:3 Laboratory-specific data - Encephalopathy:0 - Ascites:0 - Bilirubin:1.2 - Albumin:2.9 - INR:1.2 - AFP:1.5 Options (A) TACE (B) Ablation (C) Radioembolization (D) Radiotherapy (E) Resection (F) Transplant (G) Chemo (H) Palliative	(H) Palliative	<Prediction> [H. Palliative] **Rationale:** - Number of tumors: 2 (largest 7.9 cm, second 1.2 cm; segments 7, 8) - Vascular invasion: Present (1) - Extrahepatic spread: Present (1) - ECOG: 3 (poor performance status) - Liver function: Bilirubin 1.2, Albumin 2.9, INR 1.2 (mild-moderate dysfunction) - No significant ascites or encephalopathy - AFP very low (1.5) **In-context comparison & guideline basis:** - In the provided dataset, patients with extrahepatic spread and poor performance status (ECOG 2-3) are consistently assigned 'H. Palliative' care (see dataset row 10, 21, 32, 39, 76). - According to international guidelines (AASLD, EASL, BCLC), extrahepatic spread and poor functional status (ECOG ≥ 2) indicate advanced HCC, where best supportive care or palliative systemic therapy is recommended. - Locoregional therapies (arterial, ablation, radioembolization, resection, transplant) are reserved for patients without vascular invasion/extrahepatic spread and better performance status. **Treatment options for this patient:** - Palliative care (H): Focus on symptom management, quality of life, and supportive measures. - Systemic therapy may be considered, but ECOG 3 performance status limits tolerance and benefit. **Summary:** Given the advanced disease (vascular invasion, extrahepatic spread) and poor performance status (ECOG 3), the most appropriate recommendation is palliative care.	***Final Decision: H - Palliative Care** **Rationale:** - Based on the comprehensive MDT assessment and the clinical data provided: - **Tumor Burden:** Two liver tumors, largest 7.9 cm, with vascular invasion and extrahepatic spread. - **Performance Status:** ECOG 3 (significantly impaired, mostly bed/chair-bound). - **Liver Function:** Preserved synthetic function (bilirubin, albumin, INR normal), no ascites or encephalopathy. - **Contraindications to Disease-Directed Therapies:** - **Curative options** (resection, transplant, ablation) are not feasible due to advanced disease (vascular invasion, extrahepatic spread) and poor performance status. - **Local therapies** (arterial, radioembolization, radiotherapy) are contraindicated by extrahepatic spread and ECOG 3. - **Systemic therapy** (chemo, targeted) is of limited benefit and likely poorly tolerated in ECOG 3 patients. - **Goal of Care:** Focus should be on symptom management, quality of life, and supportive measures. **Therefore, the only appropriate recommendation is:** ***[H] Palliative*** No disease-directed therapy is indicated. Palliative care should be initiated, with consideration for symptom control, psychosocial support, and advanced care planning.	Result: (Logit / Cutoff) (H) Palliative (32% / 28%)

Figure 7: Additional agentic framework response comparison on HCC Tumorboard dataset - #2.(a) Single-agent in-context learning (GPT-4.1), (b) Role-based multi-agent framework (MDAgents-Advanced), and (c) CoMMA. For the role-based multi-agent, intermediate discussions are omitted, and only the final consensus is visualized. For CoMMA, class-wise logits and cutoff thresholds are transformed into percentiles.

Clinical Data	GT	(a) Single-Agent In-context Learning	(b) Role-based Multi-Agents	(c) CoMMA (Ours)
Question: Given that the patient is 70 years old, will the cancer progress in the next 12 months? Analyze the following <Clinical Data>. Answer in <Options>.				
Specimen metadata CANCER_TYPE: Colorectal Cancer SAMPLE_PE: Primary SAMPLE_CLASS: Tumor METASTATIC_SITE: Not Applicable PRIMARY_SITE: Sigmoid Colon CANCER_TYPE_DETAILED: Colon Adenocarcinoma GENE_PANEL: IMPACT410 SAMPLE_COVERAGE: 1390 TUMOR_PURITY: 20.0 ONCOTREE_CODE: COAD ... Somatic mutations ... Copy number alterations ... Structural variants ... Options (A) Yes (B) No	(B) No	<Prediction> B) No **Rationale:** - The patient's cancer is colon adenocarcinoma, localized (Stage 1-3), with no evidence of metastasis, and is microsatellite stable (MSS). - Over the past 12 months (from age 69 to 70), there have been multiple CT scans (at ages 69.091 and 69.990) showing no cancer progression. - Tumor markers (CEA) remained low and stable (from 0.9 to 3.1 ng/ml; both within the normal or mildly elevated range and with no trend indicating aggressive progression). - The patient received appropriate adjuvant chemotherapy (capecitabine, leucovorin, fluorouracil), and there is no evidence of recurrence or residual disease on imaging. - Performance status was ECOG 0 (fully active) throughout the year. - Mutation profile (APC, TP53, PIK3CA, etc.) is common in colorectal cancer but, in the absence of high-risk molecular features (e.g., MSI-high, BRAF V600E, or clear evidence of aggressive molecular subtype), does not independently predict imminent progression within a year. - No clinical, radiographic, or laboratory evidence indicates progression. **Based on similar cases in the <Dataset> (see, e.g., patient with no recurrence or progression in past 12 months and stable imaging/labs, who were predicted as 'No'), and in accordance with clinical guidelines, the likelihood of progression in the next 12 months is low.** **Final Answer:** <Prediction> B) No	**Answer: B) No** **Detailed MDT Review and Rationale:** ### 1. "Clinical Context" - **Patient:** 69-year-old White female - **Diagnosis:** Colon adenocarcinoma, ascending colon, localized (Stage 1-3) - **Microsatellite status:** MSS (Microsatellite Stable) - **Tumor Mutational Burden (TMB):** 7.8 mutations/Mb (intermediate, not high) - **Performance Status:** ECOG 0 (fully active) - **CEA:** 0.9 ng/ml at diagnosis, 3.1 ng/ml at 1 year (both within normal limits) - **Treatment:** Capecitabine, Leucovorin, Fluorouracil (standard adjuvant chemotherapy) - **Imaging:** Serial CT scans at diagnosis and at 1 year show "no evidence of cancer or progression" - **Clinical status at 1 year:** No evidence of disease (NED) ### 2. "Molecular Profile" - **Key mutations:** APC, TP53, PIK3CA, B2M, CTCF, HIST1H3E, KDR, NSD1, KDM5A - These are common in colorectal cancer, but none indicate high risk of rapid progression in the absence of residual disease. - **No evidence of high-risk features:** No MSI-H, no high TMB, no actionable fusions or amplifications. ### 3. "Current Status" - **No evidence of disease on imaging at 1 year** - **Normal tumor marker (CEA)** - **No clinical symptoms or findings suggestive of recurrence or progression** - **No evidence of metastatic disease at any time** ### 4. "Risk of Progression" - **Localized, resected colon cancer** with adjuvant chemotherapy and no evidence of disease at 1 year has a "low risk of progression in the next 12 months." - **MSS status** and **absence of high-risk molecular features** further support a favorable prognosis. - **Serial imaging and tumor markers** are negative for recurrence. ### "Conclusion" **Based on the available clinical, pathological, molecular, and radiological data, there is no evidence to suggest that this patient's colon cancer will progress in the next 12 months. The risk of recurrence or progression is low given the current status. Continued surveillance is recommended as per guidelines, but at this time, the answer is:** **B) No, the cancer will not progress in the next 12 months.**	Result: (Logit / Cutoff) (B) No (53% / 56%)

Figure 8: Additional agentic framework response comparison on MTBBench - tumor progress question. (a) Single-agent in-context learning (GPT-4.1), (b) Role-based multi-agent framework (MDAgents-Advanced), and (c) CoMMA. For the role-based multi-agent, intermediate discussions are omitted, and only the final consensus is visualized. For CoMMA, class-wise logits and cutoff thresholds are transformed into percentiles.

Clinical Data	GT	(a) Single-Agent In-context Learning	(b) Role-based Multi-Agents	(c) CoMMA (Ours)																																		
Question: Given that the patient is 54.5 years old, will the cancer have a recurrence in the next 12 months? Analyze the following <Clinical Data>. Answer in <Options> .																																						
Specimen metadata CANCER_TYPE: Colorectal Cancer SAMPLE_PE: Primary SAMPLE_CLASS: Tumor METASTATIC_SITE: Not Applicable PRIMARY_SITE: Sigmoid Colon CANCER_TYPE_DETAILED: Colon Adenocarcinoma GENE_PANEL: IMPACT410 SAMPLE_COVERAGE: 1390 TUMOR_PURITY: 20.0 ONCOTREE_CODE: COAD ... Somatic mutations ... Copy number alterations ... Structural variants ... Options (A) Yes (B) No	(A) Yes	<Prediction> (B) No Reasoning: - The patient is a 53-year-old White female with a history of stage IV (distant metastatic, AJCC IV) colon adenocarcinoma of the sigmoid colon. - She underwent systemic chemotherapy (oxaliplatin, leucovorin, fluorouracil) and has had frequent imaging and CEA monitoring. - Imaging (CT and MR) and CEA labs from age 53.5 through 54.5 consistently show: - No evidence of cancer recurrence or progression (multiple CT scans state "cancer has NOT progressed") and ("HAS CANCER: No"). - CEA levels are low and stable (all <22641.8 ng/ml). - ECOG performance status remains 0 or 1. - Most recent imaging at age 54.495 (close to present age 54.5) shows no progression or presence of cancer. - She is microsatellite stable (MSS) and has a moderate tumor mutation burden (TMB). - There is no documentation of cancer recurrence or progression in the last 12 months. - Open-source clinical guidelines indicate that, while stage IV colorectal cancer carries a high risk of recurrence, stable imaging and tumor markers over a full year suggest the risk of recurrence in the next 12 months is relatively low, especially with ongoing surveillance and no current evidence of disease. Therefore, based on the comprehensive clinical data and absence of progression or new lesions in the past year, the best-supported prediction is: B) No, the cancer will NOT have a recurrence in the next 12 months.	Answer: B) No **Rationale and Detailed Review:** ### 1. "Clinical Context" - **Patient:** 54.5-year-old White female, non-Hispanic - **Diagnosis:** Colon adenocarcinoma, sigmoid colon, AJCC Stage IV (distant disease) - **Treatment:** Received standard chemotherapy (Oxaliplatin, Leucovorin, Fluorouracil) - **Performance Status:** ECOG 0-1 throughout, indicating good functional status - **Tumor Markers:** CEA consistently low (1.1 to 20131.8 ng/ml), CA19-9 mildly elevated once (46 U/ml) - **Imaging:** Serial CT and MR scans show "no evidence of cancer progression or recurrence" at multiple time points up to age 54.495. ### 2. "Molecular and Pathological Data" - **MSI Status:** Microsatellite stable (MSS), MSI score 0.21 (low risk for hypermutated phenotype) - **Tumor Mutational Burden (TMB):** 3.9 mutations/Mb (low-intermediate, not predictive of high recurrence risk) - **Key Mutations:** - **TP53 (missense):** Common in colorectal cancer, but not specifically predictive of recurrence in isolation. - **FANCA (missense):** DNA repair gene, but not a strong driver of recurrence risk. - **CDK12 (nonsense):** Loss-of-function, may affect DNA repair, but not a high-risk marker for recurrence in MSS CRC. - **CTNNB1 (splice site):** Wnt pathway, but not a strong recurrence predictor in this context. - **Copy Number Alterations:** Mild gains (ERBB2, CDK12, RARA, SUZ12, PRKAR1A), but no high-level amplifications or deletions associated with aggressive behavior. - **No structural variants detected.** ### 3. "Clinical Course and Surveillance" - **No prior medications before MSK treatment.** - **Serial imaging (CT/MR) at ages 53.544, 53.947, 54.101, and 54.495: - All show "no evidence of active cancer" or progression. - CEA levels remain stable and low, which is reassuring. - Performance status remains good (ECOG 0-1). ### 4. "Risk of Recurrence" - **Stage IV disease** does carry a risk of recurrence, but in this patient: - **No radiological evidence of disease** for over 12 months. - **No biochemical evidence of recurrence** (CEA stable and low). - **No high-risk molecular features** (MSS, low TMB, no aggressive driver mutations). - **No clinical deterioration.** ### 5. "Summary Table" <table><tr><th>Factor</th><th>Finding</th><th>Recurrence Risk</th></tr><tr><td>Imaging</td><td>No evidence of disease</td><td>Low</td></tr><tr><td>Tumor markers</td><td>CEA stable, low</td><td>Low</td></tr><tr><td>MSI status</td><td>Stable (MSS)</td><td>Low</td></tr><tr><td>TMB</td><td>Low-intermediate</td><td>Low</td></tr><tr><td>Key mutations</td><td>No high-risk drivers</td><td>Low</td></tr><tr><td>Performance status</td><td>ECOG 0-1</td><td>Low</td></tr><tr><td>Clinical course</td><td>No progression, good response</td><td>Low</td></tr></table> **Conclusion:** Based on the comprehensive review of clinical, pathological, molecular, and imaging data, "the risk of recurrence in the next 12 months is low". There is "no current evidence of active disease" or progression, and all surveillance parameters are reassuring. **Final Decision:** **B) No, the cancer is unlikely to recur in the next 12 months given the patient's current clinical, imaging, and molecular profile. **Recommendations:** - Continue regular surveillance (imaging, CEA) as per guidelines. - Monitor for new symptoms. - Maintain multidisciplinary follow-up.	Factor	Finding	Recurrence Risk	Imaging	No evidence of disease	Low	Tumor markers	CEA stable, low	Low	MSI status	Stable (MSS)	Low	TMB	Low-intermediate	Low	Key mutations	No high-risk drivers	Low	Performance status	ECOG 0-1	Low	Clinical course	No progression, good response	Low	Result: (Logit / Cutoff) (A) Yes (49% / 47%) Agent's Contribution <table><tr><th>Agent</th><th>Contribution</th></tr><tr><td>1. Specimen metadata</td><td>~0.15</td></tr><tr><td>2. Somatic mutations</td><td>~0.35</td></tr><tr><td>3. Copy number alterations</td><td>~0.55</td></tr><tr><td>4. Structural variants</td><td>~0.10</td></tr></table>	Agent	Contribution	1. Specimen metadata	~0.15	2. Somatic mutations	~0.35	3. Copy number alterations	~0.55	4. Structural variants	~0.10
Factor	Finding	Recurrence Risk																																				
Imaging	No evidence of disease	Low																																				
Tumor markers	CEA stable, low	Low																																				
MSI status	Stable (MSS)	Low																																				
TMB	Low-intermediate	Low																																				
Key mutations	No high-risk drivers	Low																																				
Performance status	ECOG 0-1	Low																																				
Clinical course	No progression, good response	Low																																				
Agent	Contribution																																					
1. Specimen metadata	~0.15																																					
2. Somatic mutations	~0.35																																					
3. Copy number alterations	~0.55																																					
4. Structural variants	~0.10																																					

Figure 9: Additional agentic framework response comparison on MTBBench - tumor recurrence question. (a) Single-agent in-context learning (GPT-4.1), (b) Role-based multi-agent framework (MDAgents-Advanced), and (c) CoMMA. For the role-based multi-agent, intermediate discussions are omitted, and only the final consensus is visualized. For CoMMA, class-wise logits and cutoff thresholds are transformed into percentiles.